Introduction
Loss of DNA mismatch repair (MMR) has been reported in a wide variety of human malignancies and is associated with instability of microsatellite repeat sequences throughout the genome Kolodner and Marsischky 1999; Heinen et al., 2002) . A molecular phenotype associated with MMR deficiency, termed microsatellite instability (MSI), represents a consistent feature of tumors from patients with hereditary nonpolyposis colorectal cancer (HNPCC). In HNPCC families, mutations in the MMR genes, MLH1 and MSH2, account for the majority of cases. The role that defective MMR plays in tumor predisposition syndromes has been expanded by the observation that some children with congenital MLH1 mutations develop clinical features of neurofibromatosis 1 (NF1). NF1 is an autosomal-dominant inherited tumor syndrome in which affected individuals are prone to the development of both benign and malignant tumors, including myeloid leukemias (Gutmann et al., 1997) . The four MLH1-deficient children reported in the literature all died by 6 years of age with high-grade lymphomas and leukemias and exhibited classic features of NF1, such as cafe´-au-lait macules, tibial pseudarthrosis, and early-onset neurofibromas (Ricciardone et al., 1999; Wang et al., 1999) . In addition, one MSH2-deficient child has been described with leukemia and cafe´-au-lait macules (Whiteside et al., 2002) . While it is possible that these cases represent sporadic NF1, the familial clustering and the association with MMR gene defects strongly suggest that the NF1 gene is a target for MMR.
To determine whether the NF1 gene is a mutational target in MLH1-deficient cells, Wang et al. (2003) screened non-NF1 cell lines and primary tumors for NF1 mutations. In five of the 10 tumors with MSI, NF1 mutations were identified, whereas no NF1 sequence alterations were observed in five MMR-competent cell lines. In addition, a 35 base pair deletion in the murine Nf1 gene was found in Mlh1À/À mouse embryonic fibroblasts, suggesting that Mlh1 deficiency is associated with Nf1 gene mutation.
Since Nf1 þ /À mice are prone to the development of myeloid leukemia and other tumors after 12-15 months of age (Jacks et al., 1994) , we hypothesized that Mlh1 loss would increase the rate of Nf1 gene inactivation and result in an acceleration of tumorigenesis in Nf1 þ /À mice. We report that Nf1 þ /À;Mlh1À/À mice die significantly earlier than either Mlh1À/À or Nf1 þ /À mice and manifest myeloid leukemia, similar to older Nf1 þ /À mice.
Nf1 þ /À;Mlh1À/À mice die earlier than either Nf1 þ /À or Mlh1À/À mice Based on the premise that Mlh1 deficiency should increase the rate of Nf1 inactivation and accelerate the development of tumors and death in Nf1 þ /À mice, we generated Nf1 þ /À;Mlh1À/À mice on the inbred C57Bl/ 6 background. All genotypes (Nf1 þ /À, Mlh1À/À, and Nf1 þ /À;Mlh1À/À mice) were maintained for 1 year. By 12 months of age, all Mlh1À/À (n ¼ 20) and Nf1 þ / À;Mlh1À/À (n ¼ 21) mice were dead. None of the Nf1 þ /À mice (n ¼ 20) were dead, as expected from previous studies (Jacks et al., 1994) . In all, 50% of the Mlh1À/À mice were dead at 252 days, compared to 150 days for the Nf1 þ /À;Mlh1À/À mice ( Figure 1a) . In 11 of the 21 mice, we were able to perform complete necropsies. In all cases, we observed superior intrathoracic masses that compressed or enveloped the trachea. Two of these masses were adenocarcinoma of the lung, as previously reported for Mlh1À/À mice (Prolla et al., 1998) . Nine of the remaining tumors were leukemias (Figure 1b) . Six of the nine mice with leukemia were male, as reported for humans (Shannon et al., 1994) , although the number of tumors in our series is small.
Since Mlh1À/À mice are prone to lymphoma (Prolla et al., 1998; Edelmann et al., 1999) , which can histologically resemble leukemia, we performed immunohistochemical analyses using B-cell-(anti-CD45R; 01122A, Pharmingen, San Diego, CA, USA), T-cell-(anti-CD3; A0452, DAKO, Carpinteria, CA, USA), and myeloid cell-(anti-NOS2; sc651, Santa Cruz Biotechnology, Santa Cruz, CA, USA) specific antibodies, as recommended by the Mouse Models of Human Cancer Consortium hematopoietic malignancy pathology group (http://www.ncifcrf.gov/vetpath/mouseha.html). None of the nine tumors analysed in the Nf1 þ /À;Mlh1À/À mice were immunoreactive for CD3 (T-cell) or CD45R (B-cell) expression (data not shown), suggesting that these tumors were not lymphoma. To demonstrate that these tumors derived from myeloid cells and represent the hematopoietic lineage malignancies observed in children with NF1 and Nf1 þ /À mice at 15-18 months of age, we performed NOS2 immunohistochemistry, as a marker of myeloid cells. Two representative immunoreactive tumors (18049 and 18050) are shown in Figure 1c . These data collectively reinforce the contention that the malignancies observed in these Nf1 þ / À;Mlh1À/À mice are myeloid leukemias. Further studies using flow cytometry and peripheral blood analyses will be required to more completely characterize the myeloid leukemias arising in Nf1 þ /À;Mlh1À/À mice. Unfortunately, fresh tumor samples and peripheral blood were not available from our series of mice.
Nf1 inactivation in myeloid tumors arising in Nf1 þ /À;Mlh1À/À mice Recent studies have suggested that the Nf1 gene might be a target for mutational inactivation by MMR deficiency (Ricciardone et al., 1999; Wang et al., 1999 Wang et al., , 2003 Whiteside et al., 2002) . We employed three approaches to demonstrate Nf1 inactivation. First, we extracted DNA from paraffin-embedded myeloid leukemia tumor sections from Nf1 þ /À;Mlh1À/À mice and performed PCR-based loss of heterozygosity (LOH) analysis. In all tumors analysed from which goodquality DNA could be obtained from paraffin sections containing homogeneous sheets of neoplastic cells (Figure 2a ). This result is in contrast to previous studies on the effect of Mlh1 deficiency on other tumor suppressor genes, in which loss of the wild-type allele was observed. In Pten þ / À;Mlh1À/À mice, loss of the wild-type Pten allele was observed in several microdissected endometrial cancers (Wang et al., 2002) , whereas most tumors from Apc þ / À;Mlh1À/À mice were found to harbor Apc mutations in the wild-type allele (Edelmann et al., 1999; Shoemaker et al., 2000) . Second, we performed immunohistochemistry using a neurofibromin-specific antibody. In all tumors examined (n ¼ 9), there was no tumoral expression of neurofibromin. Lack of neurofibromin immunoreactivity is shown for one representative tumor (18050; Figure 2b ). In several Mlh1À/À lymphomas examined by immunohistochemistry, neurofibromin reactivity was observed in the tumor (data not shown). Neurofibromin is normally expressed in neurons in the brain as well as multiple cell types in the bone marrow and spleen, including both B and T lymphocytes (Ingram et al., 2002; Kim et al., 2002) , mast cells (Ingram et al., 2001) , and myeloid precursors (Cooper et al., 2000) . We observed positive neurofibromin immunoreactivity in normal mouse brain (not shown) and mouse bone marrow (Figure 2b ). In addition, neurofibromin immunoreactivity was also seen in Nf1 þ /À mouse brain (not shown).
In a recent study by Wang et al. (2003) , NF1 mutations were identified in multiple non-NF1 cell lines with MSI, including Mlh1À/À mouse embryonic fibroblasts. One of the colon carcinoma tumor lines, HCT116, was found to have frameshift mutations in both NF1 alleles. However, previous analysis of this cell line demonstrated NF1 protein (neurofibromin) expression (Li and White, 1996) . Further studies will be required to demonstrate a link between MLH1 deficiency and functional inactivation of the NF1 gene in human tumors.
Lastly, to provide support for the hypothesis that the Nf1 gene is a mutational target for Mlh1À/À mediated MSI, we studied MSI in myeloid tumors arising in Nf1 þ /À;Mlh1À/À mice. High-quality DNA was obtained from six tumors (18008, 18046, 18049, 18050, 18056, and 18091) . In all six tumors significant MSI was observed using multiple markers, as expected for Mlh1-deficient cells. Two tumors showed instability at all five repeats examined, three with four of five markers and one with three markers. This level of MSI would be classified as MSI high (Kabbarah et al., in preparation) . Representative MSI is shown for the GA X27 and TG X27 repeats (Figure 3a) and the data for all five repeat sequences analysed are shown in Figure 3b .
Coding sequence repeats have been implicated as mutational hotspots in tumor cells lacking MMR (Boland et al., 1998) . Despite the expected extensive MSI in the Nf1 þ /À;Mlh1À/À mouse leukemias reported here and previous studies showing high levels of MSI in multiple normal tissues of Mlh1À/À mice (Prolla et al., 1998; Yao et al., 1999) , we did not observe insertion or deletion mutations in a likely MMR polyA repeat target in Nf1 exon 3 (nucleotides 227-233; exon 3 Figure 2 Nf1 inactivation in Nf1 þ /À;Mlh1À/À mouse myeloid tumors. (a) PCR-based LOH using Nf1 primers demonstrates no reduction in the wild-type Nf1 allele in any of the four myeloid tumors analysed. An additional two Mlh1À/À; Nf1 þ /À myeloid tumors (18008 and 18056) also retained the wild-type Nf1 allele (not shown). Wild-type (Nf1 þ / þ ) and Nf1 þ /À DNA was included as an internal control. DNA from paraffin-embedded tumor sections was extracted using the QiAMP kit (Qiagen, Valencia, CA, USA) and subjected to 35 cycles of amplification using Nf1 primers as previously reported (Jacks et al., 1994) . (b) No neurofibromin immunoreactivity (NF1GRP-D; sc67, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was observed in Mlh1À/À; Nf1 þ /À myeloid tumors. One representative myeloid tumor (18050) is shown. In contrast, normal mouse bone marrow expressed neurofibromin. Mouse brain was also immunoreactive for neurofibromin (not shown). Immunohistochemical analyses of paraffin-embedded tumor sections were performed using established protocols in our laboratory (Gutmann et al., 2000) Mlh1 deficiency and Nf1 þ /À leukemogenesis DH Gutmann et al primers, 5
0 -catgtgtgctaatttgtagtga-3 0 and 5 0 -tacttaccccagcaagacat-3 0 ) in any of the six tumors analysed by direct sequencing (data not shown). In addition, we did not detect the previously reported Nf1 mutation (deletion of nucleotides 1064-1098; exon 10 primers, 5 0 -ttcatgactatttaaaggccattg-3 0 and 5 0 cagtcaatcatgaggtccaca-3 0 ) found in Mlh1À/À mouse embryonic fibroblasts (Wang et al., 2003) by single-strand conformational variant analysis (Kowalski et al., 1997; data not shown) . As the Nf1 gene is large, it is possible that other sequences in the Nf1 gene were affected by MMR deficiency. Alternatively, epigenetic silencing could explain the loss of neurofibromin expression observed in these tumors.
Further studies will be required to identify the mechanism underlying neurofibromin loss in these tumors.
NF1 and myeloid leukemogenesis
Although malignant myeloid disorders, such as juvenile chronic myeloid leukemia and monosomy 7 syndrome, are uncommon malignancies in children, children with NF1 have a 200-500-fold increased risk of developing these hematopoietic cancers (Shannon et al., 1994; Stiller et al., 1994) . Supporting data for a direct relation between NF1 and these cancers derive from several complementary studies. First, NF1 inactivation is observed in NF1-associated malignant myeloid cancers (Side et al., 1997) as well as some sporadic juvenile myeloid monocytic leukemias (Side et al., 1998) . Second, mice heterozygous for a targeted mutation in the Nf1 gene develop these myeloid cancers (Jacks et al., 1994; Shannon et al., 2001) . Third, naı¨ve irradiated mice in whom fetal Nf1-deficient hematopoietic cells have been transplanted develop a JCML-type disorder (Birnbaum et al., 2000) . Lastly, Nf1 þ /À mice have accelerated leukemogenesis after exposure to alkylating agents associated with Nf1 LOH (Mahgoub et al., 1999) .
In our study, we demonstrated loss of neurofibromin expression in the tumors arising in Mlh1-deficient mice, but could not detect Nf1 inactivation by PCRbased LOH or direct sequencing of two likely mutational targets within the Nf1 coding sequence. In human tumors, NF1 LOH was detected in 50% of cases in one study (Side et al., 1997) and none of four cases in another report (Maris et al., 1997) . In the study with 50% cases demonstrating NF1 LOH, mutations were only detected in five of eight tumors by the sensitive protein truncation test (Side et al., 1997) . While it is likely that Nf1 inactivation occurred in all human tumors as well as the mouse tumors in our study, the large size of the Nf1 gene makes comprehensive mutational analysis difficult. We hypothesize that Mlh1 deficiency leads to loss of neurofibromin expression in Nf1 þ /À;Mlh1À/À mouse leukemic cells by one of two nonmutually exclusive mechanisms: (1) epigenetic silencing of the Nf1 gene (e.g., promoter methylation) or (2) Nf1 gene inactivation by mutations in Nf1 sequences not examined in our study. Further investigation of the mechanism underlying MMR-mediated Nf1 inactivation will clarify the relation between MMR-and NF1-associated leukemogenesis. (a) Representative examples of MSI seen with GA n and TG n microsatellite repeats. Arrowheads indicate abnormal PCR products (MSI) associated with insertion or deletion of repeat elements. DNA was prepared from six high-grade leukemias (18008, 19046, 18049, 18050, 18056, and 18091) . Areas of high neoplastic cellularity were identified on the H&E stained slides, tissue (490% leukemic cells) was microdissected from unstained serial sections, and DNA extracted as previously described (Cohn et al., 2001) . PCR-based analysis of MSI was performed using two mono and three dinucleotide repeat markers (Kabbarah et al., in preparation). For each marker, PCR patterns for normal and tumor DNA were compared by running radiolabeled products sideby-side on 6% denaturing polyacrylamide gels. (b) Patterns of MSI are depicted. All six tumors show aberrant PCR products with three or more markers
